About us

Empower the immune system to fight cancer using innovative biomaterials

Symphony Biosciences is a biotechnology company developing next-generation cancer immunotherapies using advanced biomaterials and immune engineering.

Mission

Harnessing the body’s own immune system

Our mission is to help the immune system fight cancer more effectively by creating localized environments that recruit, activate, and train immune cells to recognize and destroy tumors.

Vision

Immunotherapy that’s more accessible and precise

We envision a future in which cancer immunotherapy is more accessible, effective, and precisely controlled — powerful antitumor immunity without the complexity of personalized cell therapies.

Our story

From the lab to a therapeutic platform

SymphNode builds on peer-reviewed research by our co-founders, published in Nature Biomedical Engineering (2023), showing that peritumorally implanted immunomodulatory macroporous scaffolds can systemically enhance antitumor immunity in preclinical models.

Placeholder — founding story

[Add the founding story: where the research began, the founders’ backgrounds, the institution(s) involved, and the moment the team decided to build a company.]

Research-driven. Grounded in cancer immunology, biomaterials, and translational engineering.
Translation-focused. Committed to turning breakthrough bioengineering into therapeutic products.
NCI funded. Supported by the NIH’s National Cancer Institute through a Fast-Track Phase II SBIR award.